Mickael Jean

Title: Innovations by Mickael Jean

Introduction

Mickael Jean is a notable inventor based in Rennes, France. He has made significant contributions to the field of pharmaceuticals, particularly in the area of reducing CD95-mediated cell motility. His work has implications for cancer treatment and autoimmune diseases.

Latest Patents

Mickael Jean holds a patent for "Compounds and pharmaceutical compositions for reducing CD95-mediated cell motility." This invention focuses on the reduction of CD95-mediated cancer cell motility and the treatment of B-cell tumors. The patent describes a novel family of compounds that disrupt the CD95/PLCγ1 interaction, neutralizing the CD95-mediated calcium signaling pathway and cell migration in human peripheral blood lymphocytes and Th17 cells. These compounds are intended for use as medicaments in treating various pathologies, including cancers and autoimmune inflammatory diseases.

Career Highlights

Throughout his career, Mickael Jean has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and the Université de Rennes 1. His research has contributed to advancements in medical science, particularly in understanding cell motility and its implications for disease treatment.

Collaborations

Mickael Jean has collaborated with notable colleagues, including Pierre Vacher and Patrick Legembre. Their joint efforts have furthered research in the field of pharmaceuticals and contributed to the development of innovative treatments.

Conclusion

Mickael Jean's work exemplifies the intersection of innovation and medical research. His contributions to the understanding of CD95-mediated cell motility have the potential to impact cancer treatment and autoimmune diseases significantly.